TOPLINE:
Melatonin supplementation is linked to a reduced risk for developing age-related macular degeneration (AMD) and slowing its progression, suggesting potential as a preventive therapy.
METHODOLOGY:
- Researchers analyzed data from the TriNetX database, covering electronic medical records across the United States from December 2023 to March 2024.
- The retrospective study included patients aged ≥ 50 years, divided into groups based on their history of AMD and melatonin medication codes between November 2008 and November 2023.
- Propensity score matching was used to compare melatonin users and nonusers for the risk for developing any form of AMD or the progression to exudative AMD from the nonexudative form of the condition.
TAKEAWAY:
- Use of melatonin was associated with a 58% reduction in the risk for developing AMD, according to the researchers.
- In people with nonexudative AMD, use of the supplement was linked to a 56% lower risk for progression to exudative AMD.
- The findings were consistent across age groups, suggesting melatonin’s benefits may extend to older populations at higher risk for AMD, the researchers reported.
IN PRACTICE:
“In this cohort study of 121,523 patients with no history of AMD aged ≥ 50 years, taking melatonin was associated with a decreased risk of developing AMD,” the authors of the study wrote. “Likewise, among 66,253 patients with preexisting nonexudative AMD, melatonin supplementation was negatively associated with the rate of progression to exudative AMD.”
Studies in animals and humans have shown melatonin may be a potent antioxidant and anti-inflammatory agent and have both antiangiogenic and mitochondrial-preserving properties, the authors noted. The new findings “provide a rationale for expanding clinical research on the potential therapeutic efficacy of melatonin in preventing AMD development or its progression,” they added.
SOURCE:
The study was led by Hejin Jeong, Case Western Reserve University School of Medicine, Cleveland, and was published online in JAMA Ophthalmology.
LIMITATIONS:
The study’s reliance on diagnostic codes may have limited the accuracy of identifying AMD progression. Variations in coding practices and the reporting of over-the-counter medications like melatonin could have influenced the results. The study did not control for all modifiable risk factors for AMD, which may have introduced healthy user bias.
DISCLOSURES:
The authors reported various potential conflicts of interest, including receiving personal fees and grants from various pharmaceutical companies. The study was funded by grants from the National Institutes of Health and the Cleveland Eye Bank Foundation.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
A version of this article appeared on Medscape.com.